Big costs for little gain in ovarian cancer
- PMID: 21383287
- DOI: 10.1200/JCO.2010.34.0489
Big costs for little gain in ovarian cancer
Comment on
-
RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer.J Clin Oncol. 2011 Apr 1;29(10):1252-60. doi: 10.1200/JCO.2010.28.0982. Epub 2011 Mar 7. J Clin Oncol. 2011. PMID: 21383283 Clinical Trial.
-
At what cost does a potential survival advantage of bevacizumab make sense for the primary treatment of ovarian cancer? A cost-effectiveness analysis.J Clin Oncol. 2011 Apr 1;29(10):1247-51. doi: 10.1200/JCO.2010.32.1075. Epub 2011 Mar 7. J Clin Oncol. 2011. PMID: 21383297
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
